Effect of Encouragement on Six Minute Walk Test Performance

NCT ID: NCT04586725

Last Updated: 2021-08-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-01

Study Completion Date

2024-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Peripheral artery disease (PAD) is characterised by a build up of fatty plaque in the arteries in the lower limbs, resulting in a reduction of blow flow to the muscles. Globally, it is estimated that 236 million people are living with PAD. A classic symptom of PAD is intermittent claudication (IC) which is characterised by muscle cramps in the lower limbs, typically brought on by exercise and relieved at rest. Exercise is recommended at first line treatment for IC. However to assess IC symptoms in response to an exercise study, maximal walking capacity (the furthest they can walk before it becomes too painful to walk) is typically the main measure. A patients walking capacity is assessed by a number of exercise testing protocols including the six-minute walk test (6MWT), where patients walk for six minutes with the aim to walk as far as they can in the time allotted. Patient encouragement has been shown to improve walking performance by as much as 30 meters in heart failure and respiratory disease populations. However the effect of encouragement on walking performance in people with IC is yet to be studied.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Peripheral artery disease (PAD) is characterised by atherosclerotic lesions of the arteries in the lower limbs, resulting in a reduction of blow flow (Hiatt, 2001). Globally, it is estimated that 236 million people are living with PAD, with the number of cases increasing by 24% from 2000 to 2010. A classic symptom of PAD is intermittent claudication (IC), characterised by ischemic muscle pain precipitated by exertion and relieved by rest. IC is associated with various comorbidities such as diabetes mellitus, hypertension and dyslipidaemia as well as reductions in physical function, quality of life, and balance. National and international guidelines recommend supervised exercise therapy as first line treatment for patients with IC.

To assess IC impairment in response to an exercise intervention, maximal walking capacity is typically the primary outcome in randomised controlled trials (RCT's). This involves a patient walking for as long as possible until ischemic leg symptoms, fatigue or other symptoms prevent them from continuing. This is assessed by a number of exercise testing protocols including the six-minute walk test (6MWT). The American Thoracic Society provide guidelines for performing a standardised 6MWT including verbal phrases that are conducted every minute. Conversely, Montgomery and Gardner suggest encouragement every two minutes. Encouragement has been shown to significantly affect walking performance by as much as 30 meters in heart failure and respiratory disease populations. However the effect of encouragement on walking performance in people with IC is yet to be investigated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intermittent Claudication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
Participants will be blinded to the level of encouragement they will receive during the tests

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Encouragement every minute

Patients will be randomised to six tests at one week apart

Group Type ACTIVE_COMPARATOR

Encouragement a one minute intervals

Intervention Type OTHER

Patients will perform the six exercise tests with encouragement at one minute intervals

Encouragement a two minute intervals

Intervention Type OTHER

Patients will perform the six exercise tests with encouragement at two minute intervals

Encouragement every two minutes

Patients will be randomised to six tests at one week apart

Group Type ACTIVE_COMPARATOR

Encouragement a one minute intervals

Intervention Type OTHER

Patients will perform the six exercise tests with encouragement at one minute intervals

Encouragement a two minute intervals

Intervention Type OTHER

Patients will perform the six exercise tests with encouragement at two minute intervals

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Encouragement a one minute intervals

Patients will perform the six exercise tests with encouragement at one minute intervals

Intervention Type OTHER

Encouragement a two minute intervals

Patients will perform the six exercise tests with encouragement at two minute intervals

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. \>18 years old
2. Resting ankle brachial pressure index (ABPI) \<0.9 or a reduction of ≥ 20 mmHg following exercise testing (per site protocol)
3. Able to walk unaided
4. English speaking and able to follow exercise instructions
5. Able to provide informed consent

Exclusion Criteria

1. Those who have critical limb threatening ischaemia (rest pain and/or tissue loss)
2. Unable to provide consent
3. Those presenting with any significant comorbidities or contraindications to exercise testing or training in accordance to the American College of Sports Medicine
4. Uncontrolled or symptom limiting coronary heart or pulmonary disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Coventry University

OTHER

Sponsor Role collaborator

University of Hull

OTHER

Sponsor Role collaborator

University of Salford

OTHER

Sponsor Role collaborator

University of Central Lancashire

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stefan Birkett

Lecturer In Exercise Science

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Stefan Birkett, PhD

Role: CONTACT

01772 893325

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UCentalLancashire2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

SMART Exercise for PAD
NCT06032065 RECRUITING PHASE3